Oculogica

Oculogica develops medical devices using eye-tracking technology for brain function assessment. Its FDA-cleared EyeBOX objectively aids in concussion diagnosis. This proprietary technology analyzes subtle eye movements, providing healthcare professionals quantifiable data to evaluate neurological status and brain injuries, offering a non-invasive diagnostic assessment tool.

Uzma Samadani, M.D., Ph.D., a neurosurgeon and Associate Professor, founded Oculogica in 2013. Her laboratory’s pioneering research into eye-tracking methodology provided the scientific foundation, translating academic findings into a commercial diagnostic. Rosina Samadani, Ph.D., serves as CEO, contributing medical device development expertise.

The company serves healthcare professionals, providing tools for patients with brain injuries. Oculogica aims to advance neuro-diagnostics through continuous innovation in eye-tracking solutions. Their vision is to fulfill unmet needs by delivering objective, reliable brain function assessments, enhancing patient outcomes.

High-Level Overview

Oculogica is a neuro-diagnostic company developing EyeBOX, an FDA-cleared, non-invasive eye-tracking device that aids in concussion diagnosis by analyzing over 100,000 eye movement data points during a short video task, without needing a pre-injury baseline.[1][2][3][5][7] It serves clinicians in ERs, clinics, sports medicine, and neurology—such as at Mayo Clinic and Midwest Orthopedics—solving the problem of subjective, unreliable concussion assessments that often lead to misdiagnosis, especially in mild traumatic brain injuries (mTBI).[2][4][5][6] The device provides objective results in under four minutes, supports triage, recovery tracking, and return-to-activity decisions across ages 5-67, and is reimbursable, with recent 2025 FDA expansion for normative population comparisons marking industry-leading breadth.[5][7]

Founded in 2013, Oculogica has achieved multiple FDA clearances since 2018 (including de novo and four 510(k)s), adoption by NFL teams via partnerships like TitletownTech and Microsoft, and Health Canada registration, demonstrating strong growth in clinical validation and market penetration.[2][3][5][6][7]

Origin Story

Oculogica traces its roots to 2010 at a Veterans Administration hospital in Manhattan, where neurosurgeon Dr. Uzma Samadani researched eye movements in patients in persistent vegetative states, discovering correlations between impaired eye tracking and brain injuries like concussions—published in seven peer-reviewed papers.[2][3] She founded the company in 2013 to commercialize this insight, serving as initial leader and now Scientific Advisor/Associate Professor at University of Minnesota.[1][2][6]

Her sister, Dr. Rosina Samadani (PhD from Northwestern, ex-McKinsey healthcare strategist, three-time health tech founder), joined as CEO in 2015, transforming lab research into the EyeBOX prototype.[2][3] Early traction included $600,000 from six investors in 2014 and first FDA de novo clearance in 2018.[3][5] Leadership now includes CTO Joel Sanderson (ex-enterprise security), with advisors like TitletownTech's Jill Enos and Golden Seeds partners, humanizing a family-driven mission from ORs to NFL sidelines.[1][2][3]

Core Differentiators

• Baseline-Free Objective Diagnosis: Unlike traditional tests requiring pre-injury data or subjective exams ("follow my finger"), EyeBOX delivers immediate, data-driven results via proprietary algorithms analyzing eye movements against normative databases, reducing bias in mTBI cases.[2][4][5][7]
• Broad FDA-Cleared Utility: Cleared for ages 5-67, any injury time/source (sports, accidents), triage, monitoring, recovery assessment, and therapy guidance—broadest label post-2025 expansion; also Health Canada registered and reimbursable.[5][6][7]
• Rapid, Non-Invasive Design: Tabletop device with video screen/chin rest; 4-minute test processes 100,000+ data points for concussion detection, severity scoring, and elevated intracranial pressure quantification.[3][4][7][8]
• Clinical & Real-World Validation: Used by Mayo Clinic, Rush University, NFL (via Packers/TitletownTech), with peer-reviewed backing and clinician endorsements for faster therapy access.[3][6][7]

Role in the Broader Tech Landscape

Oculogica rides the AI-driven digital health wave for objective neurology diagnostics, addressing a $27B+ global concussion market plagued by 50% misdiagnosis rates in mTBI, where subjective tools fail diverse populations.[4] Timing aligns with rising brain injury awareness post-COVID, sports safety mandates (e.g., NFL protocols), and telemedicine growth, amplified by FDA's de novo path for novel tech.[2][5] Favorable forces include AI advancements in eye-tracking metrics, regulatory support for non-invasive tools, and investor interest from healthtech VCs like TitletownTech/Golden Seeds, positioning it to influence standards in ERs, schools, and pro sports.[1][3][7] By enabling equitable, rapid care, it shifts ecosystems from reactive symptom management to proactive, data-backed interventions.[2][4]

Quick Take & Future Outlook

Oculogica's DNA of "firsts"—from de novo clearance to broadest label—positions it for expansion into global markets, elevated ICP monitoring, and AI-enhanced platforms for broader brain health (e.g., stroke triage).[5][8] Trends like wearable integration, real-world evidence mandates, and personalized neuro-recovery will propel growth, potentially via partnerships or acquisition by medtech giants. Its influence may evolve from concussion pioneer to ecosystem leader, standardizing eye-tracking as the "window into brain function," fulfilling the Samadani sisters' bet on lab-to-clinic translation.[2]